Pioglm Tablet
Metformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Aprogen Biologics Co., Ltd.
MFDS item code 201905459 · Approved 2019.07.31
This product's status changed to Expired on 2024.07.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to improve blood sugar control in patients with type 2 diabetes. It is particularly given as an adjunctive treatment when blood sugar management with metformin or pioglitazone alone is insufficient. Additionally, it can replace the combination therapy with metformin and pioglitazone. By using it along with dietary and exercise therapy, the blood sugar control effect is enhanced, and weight loss and nutritional counseling should also be conducted. This integrated management plays a crucial role in maintaining the therapeutic effect in type 2 diabetes. Therefore, this medication is used to improve blood sugar control in type 2 diabetes.
For the treatment of patients with type 2 diabetes, the dose of this medicine should be individualized based on efficacy and tolerability, without exceeding the maximum doses of each component: pioglitazone 30mg and metformin 2500mg. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients whose blood glucose is not adequately controlled with pioglitazone or metformin monotherapy: The dose should be based on the current dose of metformin or pioglitazone. Start with 1 tablet of this medicine daily and gradually adjust the dose after evaluating the adequacy of the treatment response. 2. Patients switching from combination therapy with pioglitazone and metformin: Patients switching from combination therapy with pioglitazone and metformin to this medicine may start at their current doses of pioglitazone and metformin. No studies have been conducted to investigate the safety and efficacy of switching patients from another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. 3. Patients with renal impairment: All dose adjustments should be based on a careful assessment of renal function. In general, elderly, debilitated, and malnourished patients should not be titrated up to the maximum dose of this medicine. After this medicine is administered to a patient, or when the dose is increased, the patient should be carefully monitored for adverse reactions associated with fluid retention. This medicine should generally be administered in divided doses with meals, which may reduce gastrointestinal adverse reactions caused by metformin. Sufficient time is needed to assess the adequacy of the treatment response. Ideally, the treatment response should be evaluated using glycated hemoglobin (HbA1C), which is a better indicator of long-term blood glucose control than fasting plasma glucose (FPG). HbA1c reflects blood glucose levels over the previous 2 - 3 months. In clinical use of this medicine, if blood glucose control measured by FPG has not worsened, administration for an appropriate period (8-12 weeks) is recommended to evaluate changes in HbA1C.
This medication can cause a rare side effect known as severe lactic acidosis, therefore, patients with impaired kidney function or liver dysfunction should avoid using it. Lactic acidosis can manifest as symptoms such as muscle pain, weakness, and difficulty breathing, and if these symptoms occur, the doctor should be notified immediately. This medication may pose a risk of worsening edema or heart failure in patients with heart failure, so those with heart disease should use it cautiously. Patients with active bladder cancer or a history of bladder cancer should not use this medication, and if bladder-related symptoms occur, immediate medical consultation is required. Women who are pregnant or breastfeeding should not take this medication, and its safety and efficacy have not been confirmed in children. Elderly patients may have reduced kidney function, so dosing should be carefully adjusted, and regular kidney function tests should be performed. There may be interactions with other medications, so if other medications are currently being taken, the doctor or pharmacist must be informed. In case of overdose, immediate medical attention must be sought, and particularly in cases of reduced kidney function, dialysis may be necessary. While taking this medication, excessive alcohol consumption should be avoided, and regular meals, exercise, and routine blood sugar and kidney function tests should be strictly followed.
Lactic acidosis, hypoglycemia, fatigue, myalgia, dyspnea, weakness, abdominal pain, hypothermia, hypotension, resistant bradyarrhythmia, upper respiratory tract infection, diarrhea, composite edema, peripheral edema, headache, nausea, urinary tract infection, sinusitis, dizziness, lower limb edema, weight gain, myalgia, dental disorders, worsening of diabetes, pharyngitis, anemia, hepatic failure, congestive heart failure, edema, reduced vision, diabetic macular edema, dyspepsia, insomnia, dry mouth, constipation, abdominal distension, gastroesophageal reflux disease, air trapping in the gastrointestinal tract, elevated serum creatinine, increased blood urea, fracture, blood sugar abnormality, gastroenteritis, failure to control blood sugar, hypoglycemia, elevated serum transaminase levels, increased creatine phosphokinase levels, urinary disturbances, urgency
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air and moisture. It is advisable to maintain a storage temperature between 1 to 30 degrees Celsius.
White to grayish-white oblong film-coated tablet
30 tablets (10 tablets/PTP*3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Metformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Aprogen Biologics Co., Ltd.
Pioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Dalim Biotech Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Metformin Hydrochloride · Pioglitazone Hydrochloride
Prescription medication · Combination
Nexpam Korea Co., Ltd.
CombinationPioglitazone Hydrochloride 16.53mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 850mg · Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.